ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015

Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro.

Liancheng Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.